Clinical Trial Update: EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of bevacizumab (Zirabev) in patients with severe hypoxemic COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• ZIRABEV (BEVACIZUMAB-BVZR)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Status: COMPLETED